<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717700</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG 29/21</org_study_id>
    <nct_id>NCT04717700</nct_id>
  </id_info>
  <brief_title>Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients</brief_title>
  <acronym>SABLe</acronym>
  <official_title>Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ida Bruun Kristensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense Patient Data Explorative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an&#xD;
      experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone&#xD;
      to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a&#xD;
      multicenter international set-up within the Nordic Multiple Myeloma Study Group&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an&#xD;
      experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone&#xD;
      to newly diagnosed transplant in-eligible symptomatic multiple myeloma patients in a&#xD;
      multicenter international set-up with in the Nordic Multiple Myeloma Study Group.&#xD;
&#xD;
      Each arm will include 50 patients with a total number of participants of 100 patients,&#xD;
      recruited within the NMSG collaborating countries. After induction patient will be treated&#xD;
      with continued lenalidomide-dexamethasone according to SWOG, with continuous 40mg selinexor&#xD;
      weekly in the selinexor arm (experimental arm B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 18, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased ORR in arm B (defined as ≥PR) at end of induction, defined according to IMWG response criteria</measure>
    <time_frame>Estimated at 4-8 weeks after end of induction</time_frame>
    <description>ORR at end of induction, with response defined according to IMWG response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increased VGPR rate at end of induction in arm B</measure>
    <time_frame>Estimated at 4-8 weeks after end of induction</time_frame>
    <description>VGPR rate at end of induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased rate of MRD negativity at end of induction in arm B</measure>
    <time_frame>Estimated at 4-8 weeks after end of induction</time_frame>
    <description>MRD negativity by NGS at end of induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased time to response in arm B</measure>
    <time_frame>Estimated monthly during the first 64 weeks</time_frame>
    <description>Time to at least PR from start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate toxicity rates between arm A and B, including rates of secondary primary malignancies</measure>
    <time_frame>Estimated at 4-8 weeks after end of induction</time_frame>
    <description>Comparison of toxicity rates according to NCI-CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased time to at least VGPR</measure>
    <time_frame>Estimated monthly during the first 64 weeks</time_frame>
    <description>Time to at least VGPR from start of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A VRD-light</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib sc 1.3mg/sqm once weekly Lenalidomide oral 25mg d 1-21 Dexamethasone 20mg d 1+2, 8+9 and 15+16 in 28 days cycles for up to 16 cycles followed by continuos lenalidomide-dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B -selinexor-lenalidomide/bortezomib-dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating cycles of:&#xD;
Selinexor oral 40mg once weekly Lenalidomide oral 25mg d 1-21 Dexamethasone 20mg d 1+2, 8+9 and 15+16 i 28 days cycles and Selinexor oral 80mg once weekly Bortezomib sc 1.3mg/sqm once weekly Dexamethasone 20mg d 1+2, 8+9 and 15+16 in 28 days cycles for up to 16 cycles (8 of each, alternating) followed by continuos selinexor 40mg(once weekly)-lenalidomide-dexamethasone&#xD;
for up to 16 cycles followed by continuos lenalidomide-dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor 20 MG Oral Tablet</intervention_name>
    <description>Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone</description>
    <arm_group_label>B -selinexor-lenalidomide/bortezomib-dexamethasone</arm_group_label>
    <other_name>Xpovio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib Injection</intervention_name>
    <description>Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone</description>
    <arm_group_label>A VRD-light</arm_group_label>
    <arm_group_label>B -selinexor-lenalidomide/bortezomib-dexamethasone</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide capsule</intervention_name>
    <description>Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone</description>
    <arm_group_label>A VRD-light</arm_group_label>
    <arm_group_label>B -selinexor-lenalidomide/bortezomib-dexamethasone</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Oral</intervention_name>
    <description>Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone</description>
    <arm_group_label>A VRD-light</arm_group_label>
    <arm_group_label>B -selinexor-lenalidomide/bortezomib-dexamethasone</arm_group_label>
    <other_name>Neofordex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible to enroll in this&#xD;
        study:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Willing and able to provide written informed consent in accordance with national,&#xD;
             local, and institutional guidelines. The patient must provide informed consent prior&#xD;
             to the first screening procedure&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 2. ECOG 3&#xD;
             allowed if caused by myeloma&#xD;
&#xD;
          4. Newly diagnosed multiple myeloma with treatment demanding disease as defined by IMWG&#xD;
             (Rajkumar, Dimopoulos et al. 2014) and measurable disease as defined IMWG 2016&#xD;
             criteria (Table 5) (Kumar, Paiva et al. 2016)&#xD;
&#xD;
          5. By treating physician considered in-eligible for high-dose therapy with stem-cell&#xD;
             transplant&#xD;
&#xD;
          6. Patients must have received no prior chemotherapy for multiple myeloma. Patients must&#xD;
             have received no prior radiotherapy to a large area of the pelvis (more than half of&#xD;
             the pelvis). Patients must have received no prior steroid treatment for myeloma with&#xD;
             the exception of a maximum of 14 days of treatment for symptom control (including&#xD;
             dexamethasone 40mg).&#xD;
&#xD;
          7. Adequate hepatic function within 7 days prior to C1D1:&#xD;
&#xD;
               1. Total bilirubin &lt; 1.5 × upper limit of normal (ULN) (except patients with&#xD;
                  Gilbert's syndrome who must have a total bilirubin of &lt; 3 × ULN), and&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) normal to &lt;2 × ULN.&#xD;
&#xD;
          8. Adequate renal function within 7 days prior to C1D1 as determined by estimated GFR of&#xD;
             ≥ 30 mL/min, calculated using standard formula.&#xD;
&#xD;
               1. Adequate hematopoietic function within 7 days prior to C1D1: Absolute neutrophil&#xD;
                  count ≥1000/mm3, and platelet count ≥100,000/mm3 (patients for whom &lt;50% of bone&#xD;
                  marrow nucleated cells are plasma cells). If cytopenias are due a plasma cell&#xD;
                  infiltration in the bone marrow (biopsy-proven heavy-marrow involvement, as&#xD;
                  defined by having at least 30% marrow cellularity, with &gt; 50% of the cells being&#xD;
                  malignant plasma cells (documented marrow results required)); in this case,&#xD;
                  although there are no required lower limits of normal for the blood counts, the&#xD;
                  treating physician must use his/her medical judgment as to the appropriateness of&#xD;
                  this study therapy for these patients.&#xD;
&#xD;
               2. Erythropoietin-analogues are allowed.&#xD;
&#xD;
               3. Patients must have:&#xD;
&#xD;
                    -  At least a 1-week interval from the last platelet transfusion prior to the&#xD;
                       screening platelet assessment.&#xD;
&#xD;
             However, patients may receive RBC and/or platelet transfusions as clinically indicated&#xD;
             per institutional guidelines during the study.&#xD;
&#xD;
          9. Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening. Female patients of childbearing potential and fertile male patients who are&#xD;
             sexually active with a female of childbearing potential must use highly effective&#xD;
             methods of contraception throughout the study and for 3 months following the last dose&#xD;
             of study treatment.&#xD;
&#xD;
         10. Patients must be able to take prophylactic anticoagulation as recommended by study&#xD;
&#xD;
         11. Patients with pathologic fractures, infection at diagnosis or symptomatic&#xD;
             hyperviscosity must have these conditions attended to prior to registration (i.e.,&#xD;
             intramedullary rod, I.V. antibiotics, plasmapheresis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following exclusion criteria are not eligible to enroll in this&#xD;
        study:&#xD;
&#xD;
          1. Has received selinexor or another XPO1 inhibitor previously.&#xD;
&#xD;
          2. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension,&#xD;
             uncontrolled active diabetes, active systemic infection, etc.) that is likely to&#xD;
             interfere with study procedures.&#xD;
&#xD;
          3. Known intolerance, hypersensitivity, or contraindication to glucocorticoids,&#xD;
             bortezomib, lenalidomide and selinexor.&#xD;
&#xD;
          4. Pregnant or breastfeeding females.&#xD;
&#xD;
          5. Life expectancy of less than 6 months.&#xD;
&#xD;
          6. Active, unstable cardiovascular function, as indicated by the presence of:&#xD;
&#xD;
               1. Symptomatic ischemia, or&#xD;
&#xD;
               2. Uncontrolled clinically significant conduction abnormalities (eg, patients with&#xD;
                  ventricular tachycardia on anti-arrhythmics are excluded; patients with first&#xD;
                  degree atrioventricular block or asymptomatic left anterior fascicular&#xD;
                  block/right bundle branch block will not be excluded), or&#xD;
&#xD;
               3. Congestive heart failure of New York Heart Association Class ≥3 or known left&#xD;
                  ventricular ejection fraction &lt;40%, or&#xD;
&#xD;
               4. Myocardial infarction within 6 months prior to C1D1.&#xD;
&#xD;
          7. Any active gastrointestinal dysfunction interfering with the patient's ability to&#xD;
             swallow tablets, or any active gastrointestinal dysfunction that could interfere with&#xD;
             absorption of study treatment.&#xD;
&#xD;
          8. Inability or unwillingness to take supportive medications such as anti-nausea and&#xD;
             anti-anorexia agents as recommended by the National Comprehensive Cancer Network®&#xD;
             (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and&#xD;
             anorexia/cachexia (palliative care).&#xD;
&#xD;
          9. Any active, serious psychiatric, medical, or other conditions/situations that, in the&#xD;
             opinion of the Investigator, could interfere with treatment, compliance, or the&#xD;
             ability to give informed consent.&#xD;
&#xD;
         10. Contraindication to any of the required concomitant drugs or supportive treatments.&#xD;
&#xD;
         11. Patients unwilling or unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ida B Kristensen, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanne Norseth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ida B Kristensen, MD</last_name>
    <phone>+4565411152</phone>
    <email>ida.bruun.kristensen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Gregersen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Per T Pedersen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carsten Helleberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert S Pedersen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida B Kristensen</last_name>
      <email>ida.bruun.kristensen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo Universitets Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanne Norseth</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias S Sloerdahl</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Ida Bruun Kristensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>selinexor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

